Dr. Kwatra is an associate professor of Anesthesiology, Pharmacology, and Psychiatry at Duke University Medical Center. He has a PhD in medicinal chemistry followed by several years of training in receptor biochemistry and pharmacology. This included training with 2012 Nobel laureate Dr. Robert Lefkowitz. Dr. Kwatra has been funded by the NIH to study the function of substance P/neurokinin-1 receptor (NK1R) and effect of age on cardiac GPCRs. He also led an interdisciplinary team consisting of anesthesiologists, biostatisticians, psychiatrists, and surgeons in a 2.5 million dollar, NIH-funded study to understand the molecular basis of postoperative delirium in the elderly. In 2009, Dr. Kwatra discovered a constitutively active form of NK1R in glioblastoma (GBM). Since then he has been focusing on GBM biology. Recently, he found that patient-derived GBM xenografts retain the phosphoproteomic profile of parent tumors and plans to use a panel of such xenografts and stem cells for personalized glioblastoma drug discovery. Because of his expertise in medicinal chemistry, receptor pharmacology, cell signaling, and clinical trials, Dr. Kwatra is in a unique position to develop an effective therapy against GBM.
Cory is a senior researcher and the lab manager. He was raised in Illinois and received an undergraduate degree from Duke University with a B.S. in Biology. In Dr. Kwatra’s lab, his current focus is the characterization of GBM stem cells for potential pharmacological candidates, as well as general support for the lab’s activity. He has been working in the Kwatra Lab since 2013. His expertise is to isolate glioblastoma stem cells. In addition, Cory has several years of animal work experience under his belt and is currently testing drug compounds in subcutaneous and intracranial models of glioblastoma. Cory is gathering research experience with aspirations to go into graduate school, with a side project and growing interest in computer programming.
Callie is a research assistant and 2015 Duke graduate. She graduated with a major in Biology with Distinction, concentrating in Pharmacology & Cancer Biology, as well as a minor in Environmental Science & Policy. She served as the undergraduate representative for the Campus Sustainability Committee for four years. Her experience includes: proteomic research on breast cancer stem cells in Dr. Lydia Sohn’s lab at UC Berkeley, as well as on breast cancer biomarkers and genetic signatures of metastasis with Dr. Bruce Ling and Dr. Harvey Cohen at Stanford University. In Dr. Kwatra’s laboratory, she has been focusing developing targeted therapies for GBMs with EGFRvIII since 2013. She plans to become a physician scientist with a focus on pharmacological cancer research.
Madison is a junior studying Biology with minors in Chemistry and Spanish. Previously she has done yeast genetics research in the Magwene lab at Duke and environmental epidemiology work in rural Peru. In the Kwatra lab, she is working on the neurokinin 1 receptor (NK1R) antagonist project for glioblastoma drug development.
Leora Mazumdar is a freshman at Duke University studying Biomedical Engineering. She is from El Dorado Hills, California. While in California, she gained some lab experience from taking genetic engineering classes at UC San Diego. However, this is her first time working in a research lab. In Dr. Kwatra’s lab, Leora works on data analysis and on a study on emergence delirium in awake craniotomy patients.
Amanda Haddock was introduced to the world of brain cancer when her 16 year old son, David Pearson, was diagnosed with Glioblastoma Multiforme (GBM). Though David only survived for 20 months after diagnosis, his determination to help others lives on in the work done by his family. After volunteering for a number of foundations, Amanda co-founded Dragon Master Foundation in 2013 to more fully focus on open access, big data research to impact cancer therapies. She was honored with the White House Champion of Change Award for Precision Medicine and participated in the White House Cancer Moonshot Summit. Her work as an advocate and funder has helped grow the Children’s Brain Tumor Tissue Consortium from 4 participating hospitals in the United States to more than 15 hospitals around the world. Amanda’s vision for open access research is not disease specific, and she has plans to empower research in the rare disease community and beyond. In addition to her work with research, Amanda developed and maintains a list of financial and other resources for brain cancer patients.
Steven Keating received his Ph.D. in Mechanical Engineering at the MIT Media Lab in 2016 with a minor in Synthetic Biology, and has background dual degrees in Engineering and Film from Queen’s University. Dr. Keating fuels his research with curiosity, a force he believes saved his life. He accidentally discovered he had a baseball-sized cancerous brain tumor during a voluntary academic scan. His tumor was successfully removed through awake brain surgery in 2014, and now he is a strong advocate for open patient data. His past research projects have included building-scale 3D printing, microfluidics for synthetic biology, and novel fabrication methods to explore his own brain tumor data. Steve has been featured in a short film, “The Open Patient,” and published in an O’Reilly Media book chapter, “Beyond 3D Printing: The New Dimensions of Additive Fabrication,” which summarizes the directions of his research.
Al Musella is the president and founder of the Musella Foundation For Brain Tumor Research & Information, Inc, a 501(C)3 nonprofit public charity dedicated to helping brain tumor patients through emotional and financial support, education, advocacy and raising money for brain tumor research. In 1992 his sister-in-law was diagnosed with GBM, sparking his interest in brain tumors. He soon realized there was no centralized online resource for brain tumor clinical trials. Thus, shortly after, he began the first online support group dedicated to brain tumors and collected and published a database on all relevant clinical trials. This site served as a model for the current NIH clinical trials website. Next, Dr. Musella created an online patient registry to monitor the treatments used and the respective outcomes. To date, he has provided grant funding for over 60 brain tumor research projects and emphasizes the value of nontraditional, unique approaches. He serves on numerous boards as a patient advocate, helping to shape the direction of brain tumor research. Dr. Musella was involved in the FDA approval process for Avastin and the Novocure System, and in the Medicare funding process for Gliadel, Temodar, Avastin and the Novocure system. In 1999, Al also lost his father to GBM, but he has continued to make a profound impact on brain tumor research, awareness, and support.
Recent Lab Alumni